A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS).

Authors: Wang, Ning¹ (AUTHOR), Wang, Haijun² (AUTHOR), Chen, Ying¹ (AUTHOR) trchenying@mail.ccmu.edu.cn, Wang, Yanfeng³ (AUTHOR) wangyf@cicams.ac.cn

Source: Scientific Reports. 12/30/2024, Vol. 14 Issue 1, p1-9. 9p.

Subject Terms: *ANGIOTENSIN receptors, *ENTRESTO, *OTOTOXICITY, *BALANCE disorders, *VALSARTAN, *NEPRILYSIN

The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis.

Authors: Yang, Xinyue¹ (AUTHOR), Jin, Jingjing¹ (AUTHOR), Cheng, Meijuan¹ (AUTHOR), Xu, Jinsheng¹ (AUTHOR) xjs5766@126.com, Bai, Yaling¹ (AUTHOR)

Source: Renal Failure. Dec2024, Vol. 46 Issue 2, p1-10. 10p.

Subject Terms: *HEART failure patients, *ENTRESTO, *VALSARTAN, *KIDNEY physiology, *CHRONIC kidney failure

Comparative evaluation of different brands of sacubitril/valsartan for the presence of co-crystallization.

Authors: Nair, Tiny¹ tinynair@gmail.com, Sharma, Rajat², Kumar, Viveka³

Source: European Journal of Cardiovascular Medicine. 2024, Vol. 14 Issue 4, p71-81. 11p.

Subject Terms: *X-ray powder diffraction, *ENTRESTO, *DIFFERENTIAL scanning calorimetry, *CRYSTAL lattices, *TREATMENT effectiveness

Subgroup disproportionality analysis of dementia-related adverse events with sacubitril/valsartan across geographical regions.

Authors: Kim, Seong Kyung¹, Kim, Myeong Gyu¹ kimmg@ewha.ac.kr

Source: Scientific Reports. 9/3/2024, Vol. 14 Issue 1, p1-7. 7p.

Subject Terms: *ENTRESTO, *VALSARTAN, *ANGIOTENSIN-receptor blockers, *SUBGROUP analysis (Experimental design), *SIGNAL detection

Company/Entity: UNITED States. Food & Drug Administration

Effect of sacubitril and valsartan combined with conventional therapy on patients with heart failure.

Authors: Zhenyu Wu¹ wuzy0321@163.com, Wen Cui², Guoliang Li¹, Ling Li¹, Yi Bian¹

Source: Tropical Journal of Pharmaceutical Research. Sep2024, Vol. 23 Issue 9, p1541-1547. 7p.

Subject Terms: *ENTRESTO, *PROPORTIONAL hazards models, *MULTIPLE regression analysis, *HEART failure patients, *DRUG therapy

Comparative renoprotection: Sacubitril/valsartan versus ACEI or ARB - A systematic review and meta-analysis.

Authors: Jingtao Yang¹, Chen Li¹, Cong Lu¹, Jun Cheng¹ chengjun770412@163.com

Source: Tropical Journal of Pharmaceutical Research. Feb2024, Vol. 23 Issue 2, p447-456. 10p.

Subject Terms: *FIXED effects model, *ENTRESTO, *VALSARTAN, *RANDOM effects model, *HEART failure patients, *ENZYME inhibitors

Comparison of the efficacy of combining left bundle branch pacing with either sacubitril/valsartan or enalapril in the treatment of chronic heart failure: A retrospective observational analysis.

Authors: Shengping Wang¹, Yongsheng Feng², Xiangyang Sun¹, Hualiang Gou¹, Yong Guo¹ guoyong671008@163.com

Source: Pakistan Journal of Medical Sciences. Jan/Feb2024, Vol. 40 Issue 3, Part 2, p265-270. 6p.

Subject Terms: *ENTRESTO, *VALSARTAN, *HEART failure, *ENALAPRIL, *MYOCARDIAL injury

Longitudinal Trajectory Modeling to Assess Adherence to Sacubitril/Valsartan among Patients with Heart Failure.

Authors: Mucherino, Sara¹ (AUTHOR) sara.mucherino@unina.it, Dima, Alexandra Lelia² (AUTHOR) alexandra.dima@sjd.es, Coscioni, Enrico³ (AUTHOR) coscionienrico@gmail.com, Vassallo, Maria Giovanna³ (AUTHOR) mgvassallo@hotmail.it, Orlando, Valentina¹ (AUTHOR) valentina.orlando@unina.it, Menditto, Enrica¹ (AUTHOR) enrica.menditto@unina.it

Source: Pharmaceutics. Nov2023, Vol. 15 Issue 11, p2568. 13p.

Subject Terms: *HEART failure patients, *ENTRESTO, *VALSARTAN, *PATIENT compliance, *PATIENT education

Updated insights on dementia‐related risk of sacubitril/valsartan: A real‐world pharmacovigilance analysis.

Authors: Chen, Congqin¹ (AUTHOR), Ding, Lingqing¹ (AUTHOR), Fu, Fang¹ (AUTHOR), Xiao, Jie¹ (AUTHOR) yfxjbz666@163.com

Source: CNS Neuroscience & Therapeutics. Sep2023, Vol. 29 Issue 9, p2548-2554. 7p.

Subject Terms: *ENTRESTO, *VALSARTAN, *HEART failure, *CARDIOVASCULAR agents, *HEART failure patients, *NEPRILYSIN

Company/Entity: UNITED States. Food & Drug Administration

Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan.

Authors: Myhre, Peder L.¹ (AUTHOR), Liu, Yuxi² (AUTHOR), Kulac, Ian J.³ (AUTHOR), Claggett, Brian L.³ (AUTHOR), Prescott, Margaret F.⁴ (AUTHOR), Felker, G. Michael⁵ (AUTHOR), Butler, Javed^6,7 (AUTHOR), Piña, Ileana L.⁸ (AUTHOR), Rouleau, Jean L.⁹ (AUTHOR), Zile, Michael R.¹⁰ (AUTHOR), McMurray, John J.V.¹¹ (AUTHOR), Ward, Jonathan H.⁴ (AUTHOR), Solomon, Scott D.³ (AUTHOR), Januzzi, James L.^2,12 (AUTHOR) jjanuzzi@partners.org

Source: European Journal of Heart Failure. Aug2023, Vol. 25 Issue 8, p1396-1405. 10p. 4 Charts, 1 Graph.

Subject Terms: *BRAIN natriuretic factor, *ENTRESTO, *CYCLIC guanylic acid, *VALSARTAN, *HEART failure patients, *PEPTIDES

Geographic Terms: KANSAS City (Kan.)

Process Understanding of Transamination Reaction in Chiral Pharmaceutical Intermediate Production Catalyzed by an Engineered Amine Transaminase.

Authors: Perçin, Zeynep¹ (AUTHOR) zeynep.percin@tuhh.de, Kleinbeck, Florian² (AUTHOR), Bubenheim, Paul¹ (AUTHOR), Ruch, Thomas² (AUTHOR), Liese, Andreas¹ (AUTHOR) liese@tuhh.de

Source: ChemCatChem. Nov2024, p1. 6p. 7 Illustrations.

Subject Terms: *TUBULAR reactors, *ENTRESTO, *BIOCHEMICAL substrates, *EQUILIBRIUM reactions, *BIOCONVERSION, *BIOCATALYSIS

Comparative Efficacy of Curative Effects of Sacubitril/Valsartan in HFpEF versus HFrEF Treatment.

Authors: Yi Li¹, Zifan Zhu¹, Hongbin Liu² Liuhongbin3012000@163.com

Source: Alternative Therapies in Health & Medicine. Nov2024, Vol. 30 Issue 11, p450-455. 6p.

Subject Terms: *HEART failure, *ENTRESTO, *CREATININE, *BLOOD urea nitrogen, *QUESTIONNAIRES

Effect of sacubitril--valsartan on chronic systolic heart failure and its effect on LVEF, 6-MWT, NT proBNP and NT proBNP/BNP levels.

Authors: Yan Duan¹ yanduan1329@163.com, Meimei Yu², Yan Xu³

Source: Tropical Journal of Pharmaceutical Research. Jun2023, Vol. 22 Issue 6, p1335-1340. 6p.

Subject Terms: *BRAIN natriuretic factor, *ENTRESTO, *HEART failure, *VALSARTAN, *VENTRICULAR ejection fraction, *CARDIAC pacing

Sacubitril/Valsartan vs. Standard Medical Therapy on Exercise Capacity in HFrEF Patients.

Authors: Campanile, Alfonso¹ (AUTHOR), Visco, Valeria² (AUTHOR), De Carlo, Stefania³ (AUTHOR), Ferruzzi, Germano Junior² (AUTHOR), Mancusi, Costantino⁴ (AUTHOR), Izzo, Carmine² (AUTHOR), Mongiello, Felice² (AUTHOR), Di Pietro, Paola² (AUTHOR), Virtuoso, Nicola¹ (AUTHOR), Ravera, Amelia¹ (AUTHOR), Bonadies, Domenico¹ (AUTHOR), Vecchione, Carmine^2,5 (AUTHOR), Ciccarelli, Michele² (AUTHOR) mciccarelli@unisa.it

Source: Life (2075-1729). May2023, Vol. 13 Issue 5, p1174. 10p.

Subject Terms: *AEROBIC capacity, *ENTRESTO, *HEART failure, *EXERCISE therapy, *HEART failure patients, *VALSARTAN, *EXERCISE tests

Effect of sacubitril/valsartan and ACEI/ARB on glycaemia and the development of diabetes: a systematic review and meta-analysis of randomised controlled trials.

Authors: Wang, Ruxin¹ (AUTHOR), Ye, Haowen¹ (AUTHOR), Zhao, Yongting² (AUTHOR), Wei, Jinjing¹ (AUTHOR), Wang, Ying¹ (AUTHOR), Zhang, Xiaofang³ (AUTHOR) zhangxftt@163.com, Wang, Lihong^1,4 (AUTHOR) nd66886688@gmail.com

Source: BMC Medicine. 12/17/2022, Vol. 20 Issue 1, p1-26. 26p.

Subject Terms: *RANDOMIZED controlled trials, *ENTRESTO, *VALSARTAN, *FIXED effects model, *ACE inhibitors

Earlier is Better. New Options for Acute Heart Failure: When, Who, How Much?

Authors: Nechita, Alexandru Cristian^1,2 (AUTHOR) cardionechita@yahoo.com

Source: Romanian Journal of Cardiology. Dec2022, Vol. 32 Issue 4, p167-173. 7p.

Subject Terms: *HEART failure, *ENTRESTO, *VENTRICULAR ejection fraction, *STABILITY criterion, *DEATH rate

Health‐related quality of life outcomes in PARAGON‐HF.

Authors: Chandra, Alvin¹ (AUTHOR), Polanczyk, Carisi A.² (AUTHOR), Claggett, Brian L.³ (AUTHOR), Vaduganathan, Muthiah³ (AUTHOR), Packer, Milton⁴ (AUTHOR), Lefkowitz, Martin P.⁵ (AUTHOR), Rouleau, Jean L.⁶ (AUTHOR), Liu, Jiankang³ (AUTHOR), Shi, Victor C.⁵ (AUTHOR), Schwende, Heike⁵ (AUTHOR), Zile, Michael R.⁷ (AUTHOR), Desai, Akshay S.³ (AUTHOR), Pfeffer, Marc A.³ (AUTHOR), McMurray, John J.V.⁸ (AUTHOR), Solomon, Scott D.³ (AUTHOR) ssolomon@bwh.harvard.edu, Lewis, Eldrin F.⁹ (AUTHOR)

Source: European Journal of Heart Failure. Dec2022, Vol. 24 Issue 12, p2264-2274. 11p. 1 Diagram, 4 Charts, 2 Graphs.

Subject Terms: *QUALITY of life, *ENTRESTO, *HEART failure, *VISUAL analog scale, *VENTRICULAR ejection fraction

Geographic Terms: KANSAS City (Kan.)

Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?

Authors: Nikolic, Marina¹ (AUTHOR), Novakovic, Jovana² (AUTHOR), Ramenskaya, Galina³ (AUTHOR), Kokorekin, Vladimir³ (AUTHOR), Jeremic, Nevena^2,3 (AUTHOR) nbarudzic@hotmail.com, Jakovljevic, Vladimir^1,4 (AUTHOR)

Source: Diabetology & Metabolic Syndrome. 11/23/2022, Vol. 14 Issue 1, p1-18. 18p.

Subject Terms: *ENTRESTO, *VALSARTAN, *WHITE adipose tissue, *BROWN adipose tissue, *FAT cells, *WEIGHT loss, *ADIPOSE tissues

Sacubitril/valsartan (LCZ696) ameliorates hyperthyroid-induced cardiac hypertrophy in male rats through modulation of miR-377, let-7 b, autophagy, and fibrotic signaling pathways.

Authors: Khamis, Tarek^1,2 (AUTHOR) tarekkhamis13@yahoo.com, Alsemeh, Amira Ebrahim³ (AUTHOR), Abdullah, Doaa M.⁴ (AUTHOR)

Source: Scientific Reports. 8/27/2022, Vol. 12 Issue 1, p1-13. 13p.

Subject Terms: *CARDIAC hypertrophy, *ENTRESTO, *VALSARTAN, *CELLULAR signal transduction, *RNA regulation, *BRAIN natriuretic factor

The comparative effects of sacubitril/valsartan versus enalapril on pulmonary hypertension due to heart failure with a reduced ejection fraction.

Authors: Zhao, Ying¹ (AUTHOR) Doctorzy66@163.com, Tian, Li‐guo¹ (AUTHOR), Zhang, Li‐xin¹ (AUTHOR), Ma, Tao¹ (AUTHOR), Di, Liang¹ (AUTHOR), Wang, Yan‐bo² (AUTHOR), Gu, Xin‐shun² (AUTHOR), Wang, Dan‐dan¹ (AUTHOR), Gao, Shang¹ (AUTHOR), Wang, Haiyan³ (AUTHOR)

Source: Pulmonary Circulation. Jul2022, Vol. 12 Issue 3, p1-8. 8p.

Subject Terms: *PULMONARY hypertension, *ENTRESTO, *VENTRICULAR ejection fraction, *HEART failure, *VALSARTAN